Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|February 25, 2011
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's diseaseJonathan R Evans, Roger A BarkerExpert Opinion on Therapeutic Targets|March 20, 2008
Neurotrophic factors as a therapeutic target for Parkinson's diseaseJonathan R Evans, Roger A BarkerProgress in Brain Research|December 1, 2012
Current status of clinical trials of neural transplantation in Parkinson's diseaseJonathan R Evans, Sarah L Mason, Roger A BarkerJournal of Neurology|April 11, 2013
Determinants of delayed diagnosis in Parkinson's diseaseDavid P Breen, Jonathan R Evans, Krista Farrell, et al.Journal of Parkinson'S Disease|August 14, 2013
The factor structure of the UPDRS as an index of disease progression in Parkinson's diseaseJonathan R Evans, Sarah L Mason, Caroline H Williams-Gray, et al.Movement Disorders : Official Journal of the Movement Disorder Society|June 27, 2012
Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's diseasePeter McColgan, Jonathan R Evans, David P Breen, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 20, 2013
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohortCaroline H Williams-Gray, Sarah L Mason, Jonathan R Evans, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2011
The natural history of treated Parkinson's disease in an incident, community based cohortJonathan R Evans, Sarah L Mason, Caroline H Williams-Gray, et al.Movement Disorders Clinical Practice|September 30, 2024
Validation of a 5-Year Prognostic Model for Parkinson's DiseaseJoana Ribeiro, Marta Camacho, Kirsten M Scott, et al.Brain : a Journal of Neurology|February 16, 2013
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohortSophie E Winder-Rhodes, Jonathan R Evans, Maria Ban, et al.Pageof 3